Patent intelligence · US
US 9616107
Therapy for kidney disease and/or heart failure
Therapy for kidney disease and/or heart failure
Patent details — US 9616107
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 11, 2017
- Expiration
- Apr 6, 2037
- Applicant
- Capricor Therapeutics, Inc.
- Claims
- 13
- CPC classes
- A61K, A61K38/2242, A61K47/18, A61K9/0019
Quick answer
US 9616107 (Therapy for kidney disease and/or heart failure) is held by Capricor Therapeutics, Inc.. Status: granted. Granted Apr 11, 2017. Expires Apr 6, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Capricor Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 13
- CPC classes
- A61K, A61K38/2242, A61K47/18, A61K9/0019, A61P, A61P13/12
More from Capricor Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 11801268
Methods of treating ocular inflammation and chemical injuries of the eye with extracellular vesicles
granted -
US 11759482
Methods and compositions for treating skeletal muscular dystrophy
granted -
US 10695293
Method of preventing or treating radiation-induced dermatitis with extracellular vesicles
granted -
US 10369173
Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy
granted -
US 9884076
Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy
granted -
US 9623085
Chimeric natriuretic peptide compositions and methods of preparation
granted -
US 9314507
Methods of treatment of heart failure with natriuretic peptides
granted
Frequently asked questions
What is US patent 9616107?
US 9616107 (Therapy for kidney disease and/or heart failure) is held by Capricor Therapeutics, Inc.. Status: granted. Granted Apr 11, 2017. Expires Apr 6, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9616107?
Capricor Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 43 pharmaceutical patents for this assignee.
When does US 9616107 expire?
Our index shows an expiration date of Apr 6, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.